VOR BIOPHARMA INC
NASDAQ: VOR (Vor Biopharma Inc.)
Last update: 21 hours ago19.26
0.28 (1.48%)
| Previous Close | 18.98 |
| Open | 18.99 |
| Volume | 616,581 |
| Avg. Volume (3M) | 1,180,683 |
| Market Cap | 1,043,619,968 |
| Price / Book | 0.660 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2026 |
| Diluted EPS (TTM) | -1.51 |
| Total Debt/Equity (MRQ) | 46.59% |
| Current Ratio (MRQ) | 3.88 |
| Operating Cash Flow (TTM) | -100.26 M |
| Levered Free Cash Flow (TTM) | -61.85 M |
| Return on Assets (TTM) | -55.25% |
| Return on Equity (TTM) | -125.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vor Biopharma Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | -0.63 |
|
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 43.00% |
| % Held by Institutions | 46.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Mar 2026 | 2,543,939 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 1,750,000 |
| Nextbio Capital Management Lp | 31 Mar 2026 | 999,967 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | - | 17.34 | -213 | -3,693 |
| Aggregate Net Quantity | -213 | |||
| Aggregate Net Value ($) | -3,693 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 17.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 16 Jul 2026 | Sell (-) | 213 | 17.34 | 3,693 | |
| RA CAPITAL MANAGEMENT, L.P. | 16 Jul 2026 | Option execute | 2,100,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |